ReviewPostgraduate medicine2013
Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Srdan VerstovsekPubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
21 papers cite it
this paperpooled itcites it